Matricellular protein thrombospondins: Influence on ocular angiogenesis, wound healing and immuneregulation

Current Eye Research

Volumn 39, Issue 8, 2014, Pages 759-774

  Masli, Sharmila ^a   Sheibani, Nader ^b   Cursiefen, Claus ^c   Zieske, James ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Angiogenesis; Immuneregulation; Inflammation; Lymphangiogenesis; Wound healing

Indexed keywords

THROMBOSPONDIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CELL INTERACTION; CELL MIGRATION; CELL TYPE; COMPETITIVE INHIBITION; CORNEA; DIABETIC RETINOPATHY; EYE DEVELOPMENT; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SUBRETINAL NEOVASCULARIZATION; UVEA MELANOMA; WOUND HEALING; ANIMAL; CELLULAR IMMUNITY; EYE; EYE DISEASE; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION;

ANIMALS; EYE; EYE DISEASES; HUMANS; IMMUNITY, CELLULAR; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; THROMBOSPONDINS; WOUND HEALING;

EID: 84904345609     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2013.877936     Document Type: Review

References (111)

1. Adams JC, Lawler J. The thrombospondins. Cold Spring Harb Perspect Biol 2011;3:a009712.
2. Liu A, Garg P, Yang S, Gong P, Pallero MA, Annis DS, et al. Epidermal growth factor-like repeats of thrombospondins activate phospholipase Cgamma and increase epithelial cell migration through indirect epidermal growth factor receptor activation. J Biol Chem 2009;284:6389-6402.
3. Calzada MJ, Kuznetsova SA, Sipes JM, Rodrigues RG, Cashel JA, Annis DS, et al. Calcium indirectly regulates immunochemical reactivity and functional activities of the N-domain of thrombospondin-1. Matrix Biol 2008;27: 339-351.
4. Roberts DD. THBS1 (thrombospondin-1). Atlas Genet Cytogenet Oncol Haematol 2005;9:231.
5. Ide M, Ishii H, Mukae H, Iwata A, Sakamoto N, Kadota J, et al. High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia. Respir Med 2008; 102:1625-1630.
6. Wight TN, Raugi GJ, Mumby SM, Bornstein P. Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem 1985;33:295-302.
7. Flugel-Koch C, Ohlmann A, Fuchshofer R, Welge-Lussen U, Tamm ER. Thrombospondin-1 in the trabecular meshwork:localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro. Exp Eye Res 2004;79:649-663.
8. Sekiyama E, Nakamura T, Cooper LJ, Kawasaki S, Hamuro J, Fullwood NJ, et al. Unique distribution of thrombospondin-1 in human ocular surface epithelium. Invest Ophthalmol Vis Sci 2006;47:1352-1358.
9. Masli S, Turpie B, Hecker KH, Streilein JW. Expression of thrombospondin in TGFbeta-treated APCs and its relevance to their immune deviation-promoting properties. J Immunol 2002;168:2264-2273.
10. Uchida H, Kuroki M, Shitama T, Hayashi H. Activation of TGF-beta1 through up-regulation of TSP-1 by retinoic acid in retinal pigment epithelial cells. Curr Eye Res 2008;33: 199-203.
11. Uchida H, Hayashi H, Kuroki M, Uno K, Yamada H, Yamashita Y, et al. Vitamin A up-regulates the expression of thrombospondin-1 and pigment epithelium-derived factor in retinal pigment epithelial cells. Exp Eye Res 2005;80:23-30.
12. Iruela-Arispe ML, Porter P, Bornstein P, Sage EH. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. J Clin Invest 1996;97:403-412.
13. Hyder SM, Liang Y, Wu J, Welbern V. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells. Endocr Relat Cancer 2009;16: 809-817.
14. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38: 1060-1065.
15. Fordham JB, Hua J, Morwood SR, Schewitz-Bowers LP, Copland DA, Dick AD, et al. Environmental conditioning in the control of macrophage thrombospondin-1 production. Sci Rep 2012;2:512.
16. Jaffe EA, Ruggiero JT, Falcone DJ. Monocytes and macrophages synthesize and secrete thrombospondin. Blood 1985;65:79-84.
17. Doyen V, Rubio M, Braun D, Nakajima T, Abe J, Saito H, et al. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med 2003;198: 1277-1283.
18. Li SS, Ivanoff A, Bergstrom SE, Sandstrom A, Christensson B, van Nerven J, et al. T lymphocyte expression of thrombospondin-1 and adhesion to extracellular matrix components. Eur J Immunol 2002;32:1069-1079.
19. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138:707-717.
20. Contreras-Ruiz L, Regenfuss B, Mir FA, Kearns J, Masli S. Conjunctival Inflammation in Thrombospondin-1 Deficient Mouse Model of Sjogrens Syndrome. PLoS One 2013;8: e75937.
21. Tucker RP, Hagios C, Chiquet-Ehrismann R, Lawler J, Hall RJ, Erickson CA. Thrombospondin-1 and neural crest cell migration. Dev Dyn 1999;214:312-322.
22. Greenwood JA, Murphy-Ullrich JE. Signaling of de-adhesion in cellular regulation and motility. Microsc Res Tech 1998;43:420-432.
23. Blanco-Mezquita JT, Hutcheon AE, Zieske JD. Role of thrombospondin-1 in repair of penetrating corneal wounds. Invest Ophthalmol Vis Sci 2013;54:6262-6268.
24. Li SS, Forslow A, Sundqvist KG. Autocrine regulation of T cell motility by calreticulin-thrombospondin-1 interaction. J Immunol 2005;174:654-661.
25. Wei W, Kong B, Yang Q, Qu X. Hepatocyte growth factor enhances ovarian cancer cell invasion through downregulation of thrombospondin-1. Cancer Biol Ther 2010;9: 79-87.
26. Firlej V, Mathieu JR, Gilbert C, Lemonnier L, Nakhle J, Gallou-Kabani C, et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res 2011;71:7649-7658.
27. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 2010;107:10649-10654.
28. Albo D, Shinohara T, Tuszynski GP. Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res 2002;108:51-60.
29. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP-1) dictates the course of wound healing in double-TSP-1/TSP-2-null mice. Am J Pathol 2002;161:831-839.
30. Bagavandoss P, Wilks JW. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Biophys Res Commun 1990;170:867-872.
31. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosisdependent inhibition of neovascularization by thrombospondin. Nat Med 2000;6:41-48.
32. Cursiefen C, Maruyama K, Bock F, Saban D, Sadrai Z, Lawler J, et al. Thrombospondin 1 inhibits inflammatory lymph-angiogenesis by CD36 ligation on monocytes. J Exp Med 2011;208:1083-1092.
33. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004;45:1117-1124.
34. Sheibani N, Newman PJ, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, regulates plateletendothelial cell adhesion molecule-1 expression and endothelial cell morphogenesis. Mol Biol Cell 1997;8:1329-1341.
35. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 1995;270:7304-7310.
36. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin- 1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factorbeta. J Biol Chem 1999;274:13586-13593.
37. Walton KL, Makanji Y, Chen J, Wilce MC, Chan KL, Robertson DM, et al. Two distinct regions of latencyassociated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J Biol Chem 2010; 285:17029-17037.
38. Annes JP, Rifkin DB, Munger JS. The integrin alphaVbeta6 binds and activates latent TGFbeta3. FEBS Lett 2002;511: 65-68.
39. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96: 319-328.
40. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991;32:2201-2211.
41. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990;9:963-969.
42. Knisely TL, Bleicher PA, Vibbard CA, Granstein RD. Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells. Curr Eye Res 1991;10:761-771.
43. Nishida K, Kinoshita S, Yokoi N, Kaneda M, Hashimoto K, Yamamoto S. Immunohistochemical localization of transforming growth factor-beta 1, -beta 2, and -beta 3 latencyassociated peptide in human cornea. Invest Ophthalmol Vis Sci 1994;35:3289-3294.
44. Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S. Sjogrens syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol 2009;175: 1136-1147.
45. Lee T, Esemuede N, Sumpio BE, Gahtan V. Thrombospondin-1 induces matrix metalloproteinase-2 activation in vascular smooth muscle cells. J Vasc Surg 2003;38:147-154.
46. Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 1997;235:403-412.
47. Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N. Thrombospondin-1- deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn 2003;228:630-642.
48. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997;29:354-362.
49. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis and therapeutic strategies. Surv Ophthalmol 2003;48: 257-293.
50. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-936.
51. Sheibani N, Sorenson CM, Cornelius LA, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun 2000; 267:257-261.
52. Wang S, Gottlieb JL, Sorenson CM, Sheibani N. Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes. Arch Ophthalmol 2009;127:507-513.
53. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511.
54. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998;101:982-992.
55. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93:1159-1170.
56. Wu Z, Wang S, Sorenson CM, Sheibani N. Attenuation of retinal vascular development and neovascularization in transgenic mice over-expressing thrombospondin-1 in the lens. Dev Dyn 2006;235:1908-1920.
57. Huang Q, Sheibani N. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/ Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol 2008; 295:C1647-1657.
58. Su X, Sorenson CM, Sheibani N. Isolation and characterization of murine retinal endothelial cells. Mol Vis 2003;9: 171-178.
59. Wang Y, Wang S, Sheibani N. Enhanced proangiogenic signaling in thrombospondin-1-deficient retinal endothelial cells. Microvasc Res 2006;71:143-151.
60. Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995;92:6788-6792.
61. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005;46:2210-2208.
62. Sorenson CM,Wang S, Genderon R, Paradis H, Sheibani N. Thrombospondin-1 deficiency exacerbates the pathogenosis of diabetic retinopathy. Journal of Diabetes and Metabolism 2013. doi:10.4172/2155-6156.S12:005.
63. He S, Incardona F, Jin M, Ryan SJ, Hinton DR. Thrombospondin-1 expression in RPE and choroidal neovascular membranes. Yan Ke Xue Bao 2006;22:265-274.
64. Uno K, Bhutto IA, McLeod DS, Merges C, Lutty GA. Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. Br J Ophthalmol 2006;90: 48-54.
65. Wang S, Sorenson CM, Sheibani N. Lack of thrombospondin 1 and exacerbation of choroidal neovascularization. Arch Ophthalmol 2012;130:615-620.
66. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005; 18:75-84, viii.
67. Sheibani N, Albert DM. Angiogenesis and ocular tumorigenesis. In: Tombran-Tank JBC, editor. In Ocular Angiogenesis: Diseases, Mechanisms and Therapies. Totowa, NJ: Humana Press Inc.; 2006. pp 161-171.
68. Syed NA, Windle JJ, Darjatmoko SR, Lokken JM, Steeves RA, Chappell R, et al. Transgenic mice with pigmented intraocular tumors: tissue of origin and treatment. Invest Ophthalmol Vis Sci 1998;39:2800-2805.
69. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000;12:634-640.
70. Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol 1998;140: 419-430.
71. Kyriakides TR, Zhu YH, Yang Z, Huynh G, Bornstein P. Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 2001;159:1255-1262.
72. Kyriakides TR, Maclauchlan S. The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J Cell Commun Signal 2009;3:215-225.
73. Palenski TL, Sorenson CM, Jefcoate CR, Sheibani N. Lack of Cyp1b1 promotes the proliferative and migratory phenotype of perivascular supporting cells. Lab Invest 2013;93:646-662.
74. Tang Y, Scheef EA, Wang S, Sorenson CM, Marcus CB, Jefcoate CR, et al. CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin- 2 expression. Blood 2009;113:744-754.
75. Bock F, Maruyama K, Regenfuss B, Hos D, Steven P, Heindl LM, et al. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res 2013;34:89-124.
76. Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006;103:11405-11410.
77. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-1050.
78. Platonova N, Miquel G, Regenfuss B, Taouji S, Cursiefen C, Chevet E, et al. Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1. Blood 2013;121:1229-1237.
79. Regenfuss B, Onderka J, Bock F, Hos D, Maruyama K, Cursiefen C. Genetic heterogeneity of lymph-angiogenesis in different mouse strains. Am J Pathol 2010;177:501-510.
80. Murphy-Ullrich JE, Gurusiddappa S, Frazier WA, Hook M. Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. J Biol Chem 1993; 268:26784-26789.
81. Hiscott P, Paraoan L, Choudhary A, Ordonez JL, Al-Khaier A, Armstrong DJ. Thrombospondin 1, thrombospondin 2 and the eye. Prog Retin Eye Res 2006;25:1-18.
82. Matsuba M, Hutcheon AE, Zieske JD. Localization of thrombospondin-1 and myofibroblasts during corneal wound repair. Exp Eye Res 2011;93:534-540.
83. Hiscott P, Seitz B, Schlotzer-Schrehardt U, Naumann GO. Immunolocalisation of thrombospondin 1 in human, bovine and rabbit cornea. Cell Tissue Res 1997;289:307-310.
84. Hiscott P, Armstrong D, Batterbury M, Kaye S. Repair in avascular tissues: fibrosis in the transparent structures of the eye and thrombospondin 1. Histol Histopathol 1999;14: 1309-1320.
85. Uno K, Hayashi H, Kuroki M, Uchida H, Yamauchi Y, Oshima K. Thrombospondin-1 accelerates wound healing of corneal epithelia. Biochem Biophys Res Commun 2004; 315:928-934.
86. Haddadin RI, Oh DJ, Kang MH, Villarreal Jr G, Kang JH, Jin R, et al. Thrombospondin-1 (TSP-1)-null and TSP-2-null mice exhibit lower intraocular pressures. Invest Ophthalmol Vis Sci 2012;53:6708-6717.
87. Scheef EA, Huang Q, Wang S, Sorenson CM, Sheibani N. Isolation and characterization of corneal endothelial cells from wild type and thrombospondin-1 deficient mice. Mol Vis 2007;13:1483-1495.
88. Cao Z, Wu HK, Bruce A, Wollenberg K, Panjwani N. Detection of differentially expressed genes in healing mouse corneas, using cDNA microarrays. Invest Ophthalmol Vis Sci 2002;43:2897-2904.
89. Uno K, Kuroki M, Hayashi H, Uchida H, Kuroki M, Oshima K. Impairment of thrombospondin-1 expression during epithelial wound healing in corneas of vitamin A-deficient mice. Histol Histopathol 2005;20:493-499.
90. Hori J, Vega JL, Masli S. Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye. Ocul Immunol Inflamm 2010;18:325-333.
91. Wilbanks GA, Streilein JW. Macrophages capable of inducing anterior chamber associated immune deviation demonstrate spleen-seeking migratory properties. Reg Immunol 1992;4:130-137.
92. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood-borne signals that induce ACAID. J Immunol 1991;146:3018-3024.
93. Tam AL, Gupta N, Zhang Z, Yucel YH. Quantum dots trace lymphatic drainage from the mouse eye. Nanotechnology 2011;22:425101.
94. Camelo S, Lajavardi L, Bochot A, Goldenberg B, Naud MC, Fattal E, et al. Drainage of fluorescent liposomes from the vitreous to cervical lymph nodes via conjunctival lymphatics. Ophthalmic Res 2008;40:145-150.
95. Masli S, Turpie B, Streilein JW. Thrombospondin orchestrates the tolerance-promoting properties of TGFbetatreated antigen-presenting cells. Int Immunol 2006;18: 689-699.
96. Masli S, Vega JL. Ocular immune privilege sites. Methods Mol Biol 2011;677:449-458.
97. Armant M, Avice MN, Hermann P, Rubio M, Kiniwa M, Delespesse G, et al. CD47 ligation selectively downregulates human interleukin 12 production. J Exp Med 1999;190:1175-1182.
98. Avice MN, Rubio M, Sergerie M, Delespesse G, Sarfati M. CD47 ligation selectively inhibits the development of human naive T cells into Th1 effectors. J Immunol 2000; 165:4624-4631.
99. Saban DR, Bock F, Chauhan SK, Masli S, Dana R. Thrombospondin-1 derived from APCs regulates their capacity for allosensitization. J Immunol 2010;185: 4691-4697.
100. Ng TF, Turpie B, Masli S. Thrombospondin-1-mediated regulation of microglia activation after retinal injury. Invest Ophthalmol Vis Sci 2009;50:5472-5478.
101. Miyajima-Uchida H, Hayashi H, Beppu R, Kuroki M, Fukami M, Arakawa F, et al. Production and accumulation of thrombospondin-1 in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2000;41: 561-567.
102. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 2005;46: 908-919.
103. Price AE, Reinhardt RL, Liang HE, Locksley RM. Marking and quantifying IL-17A-producing cells in vivo. PloS one 2012;7:e39750.
104. Contreras-Ruiz L, Ryan DS, Sia RK, Bower KS, Dartt DA, Masli S. Polymorphism in THBS-1 gene is associated with post-refractive surgery chronic ocular surface inflammation. Ophthalmology (in press).
105. Benito MJ, Calder V, Corrales RM, Garcia-Vazquez C, Narayanan S, Herreras JM, et al. Effect of TGF-beta on ocular surface epithelial cells. Exp Eye Res 2013;107: 88-100.
106. Gandhi NB, Su Z, Zhang X, Volpe EA, Pelegrino FS, Rahman SA, et al. Dendritic cell-derived thrombospondin-1 is critical for the generation of the ocular surface Th17 response to desiccating stress. J Leukoc Biol 2013;94:1293-1301.
107. Futagami Y, Sugita S, Vega J, Ishida K, Takase H, Maruyama K, et al. Role of thrombospondin-1 in T cell response to ocular pigment epithelial cells. J Immunol 2007;178:6994-7005.
108. Huang J, Zhou L, Wang H, Luo J, Zeng L, Xiong K, et al. Distribution of thrombospondins and their neuronal receptor alpha2delta1 in the rat retina. Exp Eye Res 2013;111:36-49.
109. Suzuma K, Takagi H, Otani A, Oh H, Honda Y. Expression of thrombospondin-1 in ischemiainduced retinal neovascularization. Am J Pathol 1999; 154:343-354.
110. Carron JA, Hiscott P, Hagan S, Sheridan CM, Magee R, Gallagher JA. Cultured human retinal pigment epithelial cells differentially express thrombospondin-1, -2, -3, and -4. Int J Biochem Cell Biol 2000;32:1137-1142.
111. Cinatl Jr J, Bittoova M, Margraf S, Vogel JU, Cinatl J, Preiser W, et al. Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents. J Infect Dis 2000;182:643-651.